- Home
- CRBU vs BIOA Comparison
CRBU vs BIOA Comparison
Compare CRBU & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- BIOA
- Stock Information
- Founded
- CRBU 2011
- BIOA 2015
- Country
- CRBU United States
- BIOA United States
- Employees
- CRBU N/A
- BIOA N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- CRBU Health Care
- BIOA Health Care
- Exchange
- CRBU Nasdaq
- BIOA Nasdaq
- Market Cap
- CRBU 179.7M
- BIOA 175.7M
- IPO Year
- CRBU 2021
- BIOA 2024
- Fundamental
- Price
- CRBU $2.68
- BIOA $5.60
- Analyst Decision
- CRBU Strong Buy
- BIOA Hold
- Analyst Count
- CRBU 3
- BIOA 4
- Target Price
- CRBU $6.67
- BIOA $5.67
- AVG Volume (30 Days)
- CRBU 1.3M
- BIOA 190.6K
- Earning Date
- CRBU 11-05-2025
- BIOA 11-06-2025
- Dividend Yield
- CRBU N/A
- BIOA N/A
- EPS Growth
- CRBU N/A
- BIOA N/A
- EPS
- CRBU N/A
- BIOA N/A
- Revenue
- CRBU $9,121,000.00
- BIOA $3,863,000.00
- Revenue This Year
- CRBU $8.06
- BIOA N/A
- Revenue Next Year
- CRBU N/A
- BIOA N/A
- P/E Ratio
- CRBU N/A
- BIOA N/A
- Revenue Growth
- CRBU N/A
- BIOA N/A
- 52 Week Low
- CRBU $0.66
- BIOA $2.88
- 52 Week High
- CRBU $3.00
- BIOA $26.62
- Technical
- Relative Strength Index (RSI)
- CRBU 64.30
- BIOA 60.70
- Support Level
- CRBU $2.24
- BIOA $5.55
- Resistance Level
- CRBU $2.39
- BIOA $6.00
- Average True Range (ATR)
- CRBU 0.19
- BIOA 0.28
- MACD
- CRBU 0.04
- BIOA 0.01
- Stochastic Oscillator
- CRBU 94.75
- BIOA 63.47
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.